Recurrence rectal cancer in pelvis. SBRT offered

Appropriate management for recurrence of rectal cancer in the pelvis where stereotactic body radiotherapy (SBRT) is considered involves a highly individualized, multidisciplinary approach focusing on local control and potential curative intent when surgery is not feasible or declined.

SBRT may be considered as a curative-intent option primarily for patients with isolated pelvic lymph node recurrence or limited extraluminal recurrences who are not candidates for surgery or who decline operative management. In this setting, delivering a regimen such as 30 Gy in 5 fractions is typical, achieving favorable local control and acceptable toxicity, although the optimal dose and fractionation remain somewhat undefined (Miller et al., 2026): Executive summary… Miller et al. 2026.

UK SABR Consortium guidance on pelvic SABR re-irradiation supports cautious dose escalation using an isotoxic approach up to 45 Gy in 5 fractions for locally recurrent rectal cancer, considering cumulative organ-at-risk constraints from previous radiotherapy (Moreno-Olmedo et al., 2025): Pelvic ster…. This approach may maximize tumor control without increasing toxicity, particularly when previous radiation fields overlap, and when higher doses are clinically justified to improve local control in non-surgical candidates (Moreno-Olmedo et al., 2025): Pelvic ster….

Preoperative radiotherapy—potentially utilizing highly conformal techniques such as intensity-modulated radiation therapy (IMRT) or particle therapy—and concurrent or sequential systemic therapy are generally favored to facilitate tumor downsizing and improve the likelihood of achieving a margin-negative (R0) resection, which remains the strongest prognostic factor for long-term survival in pelvic recurrence (Miller et al., 2026): Executive summary…. Surgery with or without intraoperative radiation therapy (IORT) is the preferred curative approach if feasible, with SBRT reserved for inoperable or declined surgery cases (Miller et al., 2026): Executive summary….

SBRT provides precise, high-dose radiation delivery ideally suited for controlling nodal or soft-tissue pelvic recurrences while sparing adjacent normal tissues, particularly in previously irradiated fields. Retrospective studies show median progression-free survival of about 12 months and overall survival around 28-39 months with low rates of high-grade toxicity, supporting its use as an ablative modality in selected patients (Miller et al., 2026): Executive summary….

Overall, management proceeds as follows:

• Evaluate for candidacy for surgery aiming for R0 resection; if feasible, consider neoadjuvant RT and systemic therapy to improve resectability (Miller et al., 2026): Executive summary….
• For patients not eligible for surgery, consider SBRT as a non-invasive ablative therapy, with treatment planning guided by cumulative prior radiotherapy doses and organ-at-risk constraints as per UK SABR national guidance (Moreno-Olmedo et al., 2025): Pelvic ster….
• Employ isotoxic dose-escalation when possible to optimize tumor control without breaching normal tissue tolerances (Moreno-Olmedo et al., 2025): Pelvic ster….
• Incorporate systemic therapy, based on molecular profile and prior treatments, concurrent with or sequential to radiation as appropriate (Miller et al., 2026): Executive summary….
• Utilize advanced imaging modalities such as high-resolution MRI and PET/CT for precise disease mapping and treatment planning (Miller et al., 2026): Executive summary….

This approach balances maximizing local control and quality of life while minimizing treatment-related toxicity, recognizing that prospective, high-level evidence is limited and ongoing audits and trials (e.g., TORCH-R) aim to refine these strategies (Moreno-Olmedo et al., 2025): Pelvic ster… Miller et al. 2026.